Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
- Conditions
- Interventions
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 22
- Registration Number
- NCT02410200
- Locations
- 🇹🇷
Research Site, Ankara, Turkey
A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
- First Posted Date
- 2015-03-12
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 25
- Registration Number
- NCT02386553
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Nemours Children's Hospital, Orlando, Orlando, Florida, United States
Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab
- First Posted Date
- 2015-03-12
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 48
- Registration Number
- NCT02386566
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
🇨🇭Research site - private practice, Luzern, Switzerland
PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Biogen
- Target Recruit Count
- 32
- Registration Number
- NCT02359344
- Locations
- 🇬🇧
Parexel International, London, United Kingdom
Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.
- Conditions
- Interventions
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 84
- Registration Number
- NCT02343159
- Locations
- 🇺🇸
Research Site, Winchester, Virginia, United States
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
- Conditions
- Interventions
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 111
- Registration Number
- NCT02342704
- Locations
- 🇬🇧
Research Site, Glasgow, Strathclyde, United Kingdom
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 13
- Registration Number
- NCT02341482
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 39
- Registration Number
- NCT02332798
- Locations
- 🇺🇸
Collaborative Neuroscience Network, LLC., Long Beach, California, United States
Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
- Conditions
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 24
- Registration Number
- NCT02323269
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Biogen
- Target Recruit Count
- 65
- Registration Number
- NCT02294851
- Locations
- 🇺🇸
WCCT Global, LLC, Cypress, California, United States
🇺🇸Covance Clinical Research Unit Inc., Dallas, Texas, United States